Connect with us

Femtech World Awards

Seven femtech innovators shortlisted for Company of the Year award

Published

on

Seven remarkable femtech innovators have made the shortlist for Femtech World’s Company of the Year award sponsored by Guidea. 

Guidea, a product design agency at the forefront of digital health design, has created transformative solutions through research, design and commercial product launch for top health companies, leading medical schools and pharma companies.

From start-up to enterprise organisation, Guidea’s collaborations aim to consistently deliver meaningful improvements for patient outcomes, raising the standard for digital healthcare.

The shortlisted companies stood out among some truly outstanding entries in one of the most competitive categories.

Congratulations to the shortlist for making the cut and many thanks to all the other submissions for taking the time to enter.

Mira is a San Francisco-based hormonal health company providing integrative care and hormonal testing. The company was founded in late 2015 by a group of scientists, engineers, OB/GYN doctors and business execs to solve the problem of the unavailability of advanced home health testing.

Mira’s mission is to develop data-driven hormonal health solutions to help women make confident health decisions during every stage of their lives – from the menstrual stage to menopause.

Fairtility, an AI innovator in the fertility space, is on a mission to advance reproductive care through the power of transparent AI to help clinicians and their patients on the reproductive care journey.

Its flagship software, CHLOE, is an AI-based decision support tool providing clinicians complete visibility into clinical and laboratory parameters crucial to improving reproductive care outcomes in IVF, fertility preservation and egg donation.

Hertility is a women’s health company on a mission to shape the future of reproductive healthcare by pioneering diagnostic testing that provides data-driven and advanced insights into reproductive health, fertility decline and the onset of menopause.

The company provides expert advice, education and access to care, aiming to reduce the time to diagnosis through advanced at-home testing and specialist gynaecological care.

Flo Health is one of most popular women’s health app globally.

With over 120 medical experts, Flo aims to support women during their entire reproductive lives and provide curated cycle and ovulation tracking, personalised health insights, expert tips and a community for women to share their questions and concerns.

Pregnolia AG is a Swiss medical technology company in the field of preterm birth detection.  The company has developed a measurement device to assess the stiffness of the cervix which serves as a crucial indicator for estimating the risk of preterm birth.

The Pregnolia System is the world’s first patented and CE-marked medical device to measure cervical stiffness. Existing proof-of-concept data confirm that cervical stiffness correlates with earlier births and the diagnostic capabilities are significantly better than the cervical length measured by ultrasound, which is the golden standard in preterm birth diagnosis today.

Hormona is a data-driven women’s health company targeting hormonal imbalances.

Founded in 2020 by Swedish natives Karolina Lofqvist and Jasmine Tagesson, Hormona is the developer behind an at-home urine test that measures the three most important female hormones quantitatively in less than 15 minutes, removing the need for a lab and helping women monitor their hormone levels from the comfort of their homes.

Through regular testing, the company aims to support women with issues, such as irregular cycles, hormonal imbalance, PCOS, perimenopause, menopause and infertility, and help them live in harmony with their hormones.

ARC Fertility is a leader in the IVF fertility market providing products and services to the fertility community. ARC aims to offer affordable fertility treatment packages, refund guarantees and finance options to people living with infertility.

With more than 27 years of experience, ARC has the largest network of board-certified fertility specialists in the United States and supports women and couples on their infertility journey with resources and tools on education, treatment management and stress reduction.

 

To receive the Femtech World newsletter, sign up here.

Femtech World Awards

Femtech World reveals Fertility Innovation shortlist

Published

on

Six fertility innovators have made the shortlist for Femtech World’s Fertility Innovation award sponsored by Apryl. Check them out below.  

Apryl is a fertility benefits platform that helps employers attract and retain top talent while tackling diversity and inclusion.

The company helps employers support their employees with fertility and family planning benefits, including consultation, access to clinics, treatments and adoption.

Through the Fertility Innovation Award, sponsored by Apryl, Femtech World aims to shine a light on the life-changing work of those developing innovative fertility solutions.

The six finalists will now go-head-to-head, with the winner announced at a virtual ceremony on May 2.

 

Selectivity is a start-up focused on universalising access to fertility treatments. The company is working towards developing better, accessible and cost-saving assisted reproductive devices that are promising to transform the patient journey to conception. 

Future Fertility is the first company in the world to address this significant gap in treatment planning and patient expectation management by developing AI-powered oocyte assessment software that provides patients and their fertility care teams with personalised egg quality insights.

The software uses deep learning technology to analyse 2D images of mature oocytes, providing egg quality scores that have been validated in laboratories and clinical practice and are proven to correlate directly with reproductive outcomes.

Proov is a diagnostics company offering medical grade at-home tests and a support platform that is clinically proven to help those looking to conceive do so faster and more cost-effectively.

Proov founder, Dr Amy Beckley, PhD, created the core Proov technology after her own battle with infertility. The company now boasts over 10 products and continues to innovate to bring additional solutions to child bearing people and their partners.

Fairtility is advancing reproductive care through the power of transparent AI to help clinicians and their patients on the reproductive care journey.

The company believes that transparency is critical when AI intersects with human life. Its flagship software, CHLOE, is a transparent AI-based decision support tool providing clinicians with visibility into clinical and laboratory parameters crucial to improving reproductive care outcomes in IVF, fertility preservation and egg donation.

Embie aims to optimise fertility treatments with personalised, connected care. The Embie Clinic platform seeks to empower clinics with real-time, data driven insights, while reducing the administrative and cognitive load for the clinic.

Plan Your Baby is a telehealth fertility clinic on a mission to reduce practical and financial barriers to IVF.

The platform leverages cutting-edge technology to provide support from preconception to birth, while addressing 13 of the main treatable causes of infertility.

Continue Reading

Femtech World Awards

Seven start-ups to go head-to-head at Femtech World Awards

Published

on

Seven femtech start-ups have made the shortlist for Femtech World’s OB/GYN Innovation award sponsored by Cross-Border Impact Ventures

CrossBorder Impact Ventures is on a mission to revolutionise venture capital investing in health technology. The company invests in early-growth stage health technology companies commercialising medical devices, diagnostics, therapeutics and digital health innovations and leveraging cutting-edge technologies like AI and machine learning.

All financed innovations are relevant to women, children and adolescent health and located in North America, Europe and Israel with ability to scale technologies to Emerging Markets.

The shortlisted companies in the OB/GYN Innovation category stood out among some truly remarkable entries from all over the world.

The seven shortlisted entries will soon be judged by the category sponsor, with the ultimate winner announced at a virtual event on May 2.

 

Nesa Medtech is a a medical device start-up on a mission to transform women’s health by developing minimally invasive surgical solutions.

The company’s flagship product is a novel, minimally invasive and uterus-preserving technology aimed at treating uterine fibroids, a condition which has profound impacts on healthcare delivery and costs worldwide.

EndoCure aims to revolutionise the diagnosis of endometriosis with a novel robotic AI-powered ultrasound. The system is specifically designed to detect endometriosis lesions, which currently can’t be detected by imaging tools.

The ability to detect such lesions, EndoCure says, is crucial as the pain associated with endometriosis can be excruciating and life-altering. This capability not only promises to shorten the diagnostic journey for millions of women suffering from endometriosis but also aims to enhance the accuracy of diagnosis.

Hale offers a virtual-first care model that aims to reshape patient journeys for gynaecological conditions.

The platform leverages cutting-edge technology and interdisciplinary expertise to provide comprehensive care solutions, including online consultations, care navigation support, digital prescriptions and diagnostic fast-tracking processes.

 

Lasa Health is a health tech company supporting the diagnosis and management of pelvic pain disorders. The company uses AI and machine learning to screen patients for the potential causes of chronic pelvic pain.

Its algorithm, according to its developers, is able to catch conditions that would have otherwise been missed by physicians. The platform provides personalised recommendations for physicians to review and discuss with patients. 

Sonio is an AI solution for prenatal screening and diagnosis with over five years of research and collaborations between leading experts in foetal medicine and AI.

Sonio’s goal is to support foetal ultrasound practitioners in prenatal screening and diagnosis by assuring the completeness of their examination and increasing the accuracy of their patient scan results.

Based in Switzerland, Aspivix is a medical device company on a mission to reimagine and modernise gynaecology.

Its flagship product, Carevix, is the world’s first suction cervical stabiliser clinically proven to reduce pain and bleeding associated with transcervical procedures commonly performed in gynaecology, including IUD insertion, hysteroscopy, cervical biopsies and fertility treatments.

Yeda is developing a sustainable device that aims to support women’s pelvic floor and improve bladder control. The company is committed to improving women’s quality of life by offering personalised and user-friendly treatment.

Its device promises to disrupt the market by reducing hospital visits and providing gynaecologists with an innovative tool for their patients.

Continue Reading

Femtech World Awards

Femtech World reveals Research Project of the Year shortlist

Published

on

Four femtech innovators have been shortlisted for Femtech World’s Research Project of the Year, sponsored by Future Fertility.

Backed by the industry’s largest and most diverse oocyte dataset of over 120,000 images and reproductive outcomes, Future Fertility is the leader in AI-powered oocyte quality assessment.

There were more than 120 entries for this year’s Femtech World Awards, with the Research Project category attracting a number of very high-quality entries.

Shortlisted entries will assessed by the category sponsor, with the winner announced at an online ceremony on May 2.

 

Matrix is a 21st century replacement, an evolution and revolution of the speculum, which has not changed in design and operation since the Roman Era. The speculum is gynaecological tool, which is used by clinicians to access the reproductive organs of a woman and perform various assessments and procedures.

Matrix’s Health and Care is on a mission to eliminate the current invasive gynaecological instrument and transform gynaecological protocols through women-led design innovation.

FlowSense is the world’s first accessible period blood detection device, empowering visually impaired women to independently manage their menstrual hygiene. There are no existing products in the market designed to detect period blood for the visually impaired.

FlowSense aims for an accurate vaginal fluid detection that not only identifies menstruation changes but can provide a comprehensive approach to vaginal health through the analysis of pH vaginal health and related symptoms.

There still is a large gender gap in knowledge and data in healthcare. theblood is the first start-up in Europe to use menstrual blood as a non-invasive blood test to help solve women’s health problems.

The company’s at-home test allows women to analyse their menstrual blood on a monthly basis and gain thus new insights into their state of health.

Hormona is the developer behind an at-home urine test that measures the three most important female hormones quantitatively in less than 15 minutes, removing the need for a lab and helping women monitor their hormone levels from the comfort of their homes.

Through regular testing, the company aims to support women with issues, such as irregular cycles, hormonal imbalance, PCOS, perimenopause, menopause and infertility, and help them live in harmony with their hormones.

 

To receive the Femtech World newsletter, sign up here.

Continue Reading

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.